SARS-CoV-2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

Sara Protić, Milica Crnoglavac Popović, Nevena Kaličanin, Olivera Prodanović, Milan Senćanski, Jelena Milićević, Kristina Stevanović, Vladimir Perović, Slobodan Paessler, Radivoje Prodanović, Sanja Glišić

Research output: Contribution to journalArticlepeer-review

Abstract

The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.

Original languageEnglish (US)
Article numbere202400091
JournalChemistryOpen
Volume13
Issue number11
DOIs
StatePublished - Nov 2024

Keywords

  • antiviral therapy
  • drug repurposing
  • fidaxomicin
  • in vitro
  • SARS-CoV-2 PLpro

ASJC Scopus subject areas

  • General Chemistry

Fingerprint

Dive into the research topics of 'SARS-CoV-2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment'. Together they form a unique fingerprint.

Cite this